PuriActives® 7-DHC

Vitamin D3 Precursor for Skin Resilience & Renewal

INNOVATION IN SKIN SCIENCE

PURIPHARM BRAND ARCHITECTURE

7-DHC: THE RESILIENCE ANCHOR

ADDRESSING MODERN SKIN STRESS

BEYOND BASIC MOISTURE

MARKET DEMAND FOR RESILIENCE

WHAT IS 7-DEHYDROCHOLESTEROL?

PURIACTIVES® 7-DHC BENEFITS

THE BIOLOGICAL PATHWAY

CELLULAR STRESS RESILIENCE

POST-SUN COMFORT

BIOLOGICAL BALANCE & RENEWAL

SUBSTANTIATION SUMMARY

HSP MRNA UPREGULATION

PILOT STUDY RESULTS

CLAIM DIRECTION GUIDE

TECHNICAL GUIDANCE

PRODUCT CONCEPT PROTOTYPES

COMPLIANCE & SAFETY

THE MARKETING EDGE

Retinal (Retinaldehyde) Market Outlook & Strategic Analysis Report

I. Background:

The “EU Vitamin A Restriction” Shaking the Industry

The formal implementation of Regulation (EU) 2024/996 marks a pivotal regulatory turning point for Vitamin A derivatives in the skincare industry.

1. Key Regulatory Highlights

  • Concentration Thresholds: From November 1, 2025, new face and leave-on products must not exceed 0.3% Retinol Equivalent (RE); body lotions are limited to 0.05% RE.
  • Grace Period: Non-compliant products already on the market must be withdrawn by May 1, 2027.
  • Mandatory Labeling: Products must include a warning: “Contains Vitamin A. Consider your daily intake before use.”

2. Industry Ripple Effects

This regulation forces a paradigm shift from “High Concentration” to “High Efficiency.” Retinal (Retinaldehyde), the direct precursor to Retinoic Acid, has emerged as the premier alternative to Retinol, offering superior performance within the new legal limits.

II. Core Value:

Why Retinal is the “Optimal Solution”

Under the 0.3% concentration cap, Retinal provides a much higher “performance ceiling” compared to Retinol.

  • Conversion Efficiency: Retinal requires only one conversion step to become Retinoic Acid (the active form), whereas Retinol requires two. Research indicates Retinal’s bio-activity is approximately 10-11 times more efficient than Retinol.
  • Compliance Advantage: At the 0.3% EU limit, Retinal can deliver anti-aging results comparable to unregulated high-concentration Retinol (1.0%+) products of the past.
  • Antibacterial Benefits: Unlike Retinol, Retinal possesses natural antimicrobial activity, making it a unique solution for the “adult acne & anti-aging” dual-segment.

III. Technical Strategy:

Advanced Delivery & Synergistic Formulas

To overcome Retinal’s inherent instability, the following next-generation combinations are recommended:

1. Retinal + Silybin (Phyto-Retinol Strategy):

  • Silybin is highlighted as the premier plant-based Retinol alternative. It promotes collagen regeneration via “Retinoid-like” pathways without the irritation.
  • Its potent anti-inflammatory properties significantly down-regulate pro-inflammatory cytokines, mitigating the potential irritation often associated with Retinal.

2. Retinal + Hexylresorcinol (Multi-Target Aging):

  • Hexylresorcinol inhibits melanin synthesis while reinforcing the dermal support structure.
  • This synergy achieves a “1+1>2” effect for intensive wrinkle reduction and skin tone brightening.

IV. Core Competitive Advantages of PuriPharm

As a leader in Nano-Delivery Systems (NDS), PuriPharm is uniquely positioned to solve the stability and penetration challenges of Retinal:

1. Pharmaceutical-Grade Nano-Encapsulation (NanoActive®)

  • Solving Stability Issues: Retinal is extremely sensitive to light and oxygen. PuriPharm’s Nano-Liposome technology isolates the active from environmental factors, ensuring long-term potency.
  • Enhanced Skin Penetration: With particle sizes typically below 30nm, NanoActive® RAL (Retinal) penetrates the skin barrier more effectively than traditional formulations, reaching the deeper dermis.
  • Reduced Irritation (De-noising): Controlled release technology ensures a steady delivery of actives, minimizing the “Retinoid reaction” (redness and peeling).

2. Comprehensive Synergistic Ingredient Portfolio

PuriPharm provides a complete suite of nano-encapsulated actives, including NanoActive® RAL, NanoActive® Silybin, and NanoActive® Hexylresorcinol.

Universal Nano-Compatibility allows formulators to combine these “Triple Threat” ingredients seamlessly, ensuring physical stability and a premium, non-greasy skin feel.

3. Professional R&D & Data Support

  • Backed by a founding team with deep pharmaceutical backgrounds, PuriPharm provides robust in-vitro and clinical efficacy data. This assists global brands in justifying their claims and navigating strict EU labeling requirements.

V. Strategic Opportunities for the International Market

  1. Concentration-to-Efficiency Rebranding: Help brands leverage 0.3% Retinal Nano-products to outperform 1.0% Retinol competitors in efficacy.
  2. Global Compliance Transition: Provide ready-to-use, EU-compliant ingredient solutions and stability dossiers for brands looking to enter or stay in the European market.
  3. Custom NDS Development: Utilize the NDS platform to create exclusive “Retinal + X” nano-complexes, building a proprietary technical moat for the brand.

VI. Conclusion

The EU Vitamin A restriction is not an end, but the beginning of the “Era of Scientific Anti-Aging.” By utilizing PuriPharm’s Nano-Delivery Systems to master the stability and delivery of Retinal, brands can achieve market dominance in the post-retinol landscape.

NanoActive Oridonin(Liposomal Oridonin)

Stable Water-Soluble Oridonin

Product Overview

NanoActive Oridonin represents a groundbreaking advancement in cosmetic active ingredients, combining the potent bioactive properties of oridonin with state-of-the-art liposomal delivery technology. As part of PuriPharm’s prestigious NanoActive® series, this innovative ingredient addresses multiple signs of skin aging through a sophisticated multi-target approach, making it an exceptional choice for premium skincare formulations targeting skin tone improvement and overall skin revitalization.

Oridonin, a bioactive diterpenoid compound naturally occurring in Rabdosia rubescens, has been extensively studied for its remarkable biological activities. However, its practical application in cosmetic formulations has been historically limited due to poor water solubility and stability challenges. PuriPharm has successfully overcome these obstacles through advanced liposomal encapsulation technology, creating a stable, water-soluble form that maintains full bioactivity while ensuring optimal skin penetration and sustained release.

Product Identification

Key Benefits

NanoActive Oridonin delivers comprehensive skin tone enhancement through its unique ability to address three fundamental visible skin pigments that serve as true markers of skin aging. This triple-action mechanism sets it apart from conventional brightening ingredients that typically target only melanin production.

Melanin Reduction

NanoActive Oridonin effectively inhibits melanogenesis through multiple pathways, reducing the appearance of hyperpigmentation, age spots, and uneven skin tone. The liposomal delivery system ensures that the active compound reaches melanocytes in the basal layer of the epidermis, where it modulates tyrosinase activity and interrupts the melanin synthesis cascade. Clinical observations have demonstrated significant improvements in skin luminosity and reduction in pigmented lesions with consistent application.

Hemoglobin Modulation

Unlike most brightening agents, NanoActive Oridonin also addresses vascular-related skin discoloration by modulating hemoglobin visibility. This is particularly beneficial for reducing the appearance of facial redness, telangiectasia, and post-inflammatory erythema. The compound’s anti-inflammatory properties help calm irritated skin while strengthening capillary walls, resulting in a more uniform and balanced complexion. This dual-action approach to both melanin and hemoglobin makes it exceptionally effective for individuals with complex skin tone concerns.

Collagen Synthesis Enhancement

Beyond pigment correction, NanoActive Oridonin actively promotes collagen synthesis in dermal fibroblasts. This pro-collagen activity helps restore skin firmness and elasticity while reducing the appearance of fine lines and wrinkles. The compound stimulates fibroblast proliferation and upregulates type I collagen production, contributing to overall skin rejuvenation. This comprehensive approach ensures that skin not only appears more even-toned but also demonstrates improved texture and youthful resilience.

Mechanism of Action

The efficacy of NanoActive Oridonin stems from its sophisticated multi-target mechanism that addresses skin aging at the cellular level. Understanding these mechanisms is essential for formulators seeking to maximize the ingredient’s potential in their product development.

Upon application, the liposomal carriers penetrate the stratum corneum through intercellular lipid pathways, delivering the encapsulated oridonin to targeted skin layers. The phospholipid bilayer structure of the liposomes mimics natural cell membranes, facilitating fusion with keratinocyte membranes and enabling efficient intracellular delivery. This targeted delivery system significantly enhances bioavailability compared to conventional formulations, ensuring that a higher percentage of the active compound reaches its intended site of action.

Once released, oridonin interacts with multiple cellular signaling pathways. It modulates the expression of melanogenesis-related enzymes, including tyrosinase, TRP-1, and TRP-2, through downregulation of MITF (microphthalmia-associated transcription factor). Simultaneously, it activates TGF-beta signaling pathways that promote collagen synthesis while inhibiting MMP enzymes responsible for collagen degradation. This coordinated action results in visible improvements in skin tone, texture, and overall appearance.

Technical Advantages

The liposomal encapsulation technology employed in NanoActive Oridonin represents a significant advancement in cosmetic ingredient delivery systems. This sophisticated approach addresses the inherent challenges associated with oridonin while unlocking its full therapeutic potential for skincare applications.

  • Enhanced Stability: The liposomal encapsulation protects oridonin from oxidation, photodegradation, and chemical degradation, ensuring consistent potency throughout the product shelf life. This stability enhancement allows formulators to create products with extended shelf stability without compromising efficacy.
  • Superior Water Solubility: The transformation from a poorly water-soluble compound to a readily dispersible liposomal suspension enables seamless integration into aqueous formulations, expanding formulation possibilities for serums, essences, and lightweight moisturizers.
  • Optimized Skin Penetration: Liposomal carriers enhance transdermal delivery by facilitating passage through the stratum corneum and promoting accumulation in the epidermis and upper dermis, where the active compound can exert its beneficial effects on melanocytes and fibroblasts.
  • Sustained Release Profile: The controlled release mechanism ensures prolonged activity at the target site, reducing the frequency of application needed to achieve optimal results while minimizing potential irritation from concentrated exposure.
  • Biocompatible Delivery System: The phospholipid-based liposomes are biocompatible and well-tolerated by all skin types, including sensitive and compromised skin barriers, making NanoActive Oridonin suitable for a wide range of cosmetic applications.

Recommended Applications

NanoActive Oridonin’s versatile profile makes it an ideal active ingredient for various premium skincare formulations. Its water-soluble nature and excellent stability allow for flexible incorporation into diverse product formats, enabling formulators to create innovative solutions for comprehensive skin tone correction and anti-aging benefits.

  • Brightening and whitening serums targeting hyperpigmentation and age spots
  • Anti-aging creams and lotions with comprehensive rejuvenation benefits
  • Skin tone evening treatments for redness-prone and uneven complexions
  • Post-procedure recovery formulations designed to calm and restore skin
  • Premium facial essences and treatment concentrates for intensive care
  • Multi-functional day and night creams with tone-correcting properties

About PuriPharm Co. Ltd.

PuriPharm Co. Ltd. is a leading innovator in the development and manufacturing of high-performance cosmetic active ingredients. With a strong commitment to scientific research and technological advancement, PuriPharm has established itself as a trusted partner for cosmetic formulators worldwide, delivering cutting-edge solutions that meet the evolving demands of the global beauty industry.

The company’s two flagship brand series, PuriActives® and NanoActive®, represent the pinnacle of cosmetic ingredient innovation. The PuriActives® series focuses on purified, high-potency active compounds derived from natural sources, while the NanoActive® series showcases PuriPharm’s expertise in advanced delivery systems, including liposomal, nanoemulsion, and encapsulation technologies. Together, these product lines offer formulators a comprehensive portfolio of solutions for creating next-generation skincare products.

PuriPharm maintains rigorous quality standards throughout its manufacturing processes, with state-of-the-art facilities equipped for advanced extraction, purification, and nano-formulation technologies. The company’s dedicated research and development team continuously explores new frontiers in cosmetic science, ensuring that PuriPharm remains at the forefront of ingredient innovation. By combining traditional botanical wisdom with modern scientific methodologies, PuriPharm creates ingredients that deliver measurable results while meeting the highest standards of safety and efficacy.

Contact Information

For product inquiries, technical support, or partnership opportunities:

PuriPharm Co. Ltd.

Website: www.puripharm.com

Product Series: PuriActives® | NanoActive®

NanoActive RETINAMIDE

NanoActive RETINAMIDE is an innovative ingredient that combines the anti-aging benefits of retinamide with the advantages of nano-technology, designed to enhance skin penetration, stability, and bioavailability.Continue reading

PuriPharm Co. Ltd. and Kunming Medical University Collaborate to Achieve Breakthrough in Antidepressant

Press Release in English

PuriPharm Co. Ltd. and Kunming Medical University Collaborate to Achieve Breakthrough in Antidepressant ResearchNovel Nano-Formulation Technology Enhances Efficacy of Tetrahydrocurcumin PuriPharm Co. Ltd. recently announced a significant research breakthrough in collaboration with Associate Professor Guo Ying’s team from the Department of Pharmacology, Kunming Medical University. The study confirms that PuriPharm’s proprietary nano-tetrahydrocurcumin (THCN) demonstrates superior efficacy in improving lipopolysaccharide (LPS)-induced depressive-like behaviors and neuroprotection in mice compared to traditional tetrahydrocurcumin (THC). The findings were published in Acta Universitatis Medicinalis Anhui. Research Highlights ·Enhanced Therapeutic Efficacy: THCN, developed using PuriPharm’s advanced nano-formulation technology, showed superior anti-anxiety effects in long-term administration compared to THC. ·Dual Neuroprotective Mechanisms: THCN alleviated prefrontal cortex demyelination by promoting GFAP expression, while THC mainly exerted its effects through TLR4 pathway inhibition. ·Improved Stability and Bioavailability: The nano-formulation optimized drug delivery, enabling sustained efficacy at a lower dose (10 mg/kg), a critical step toward clinical translation. Technology Value and Collaboration PuriPharm’s nano-formulation platform addresses challenges such as poor solubility and low stability of natural compounds. This collaboration underscores the potential of interdisciplinary research in advancing novel antidepressant therapies. “Our partnership highlights the power of industry-academia collaboration,” said Associate Professor Guo Ying. “THCN offers a promising new approach for depression treatment, and we look forward to further clinical development.” About PuriPharm Co. Ltd. PuriPharm specializes in nanomedicine and innovative drug delivery systems, committed to translating cutting-edge science into clinical solutions. With a focus on oncology and neurological disorders, the company leverages its expertise in nanotechnology to develop next-generation therapeutics. Media Contact PuriPharm Co. Ltd.  Email: service@puripharm.com Website: www.puriactives.com

You need to add a widget, row, or prebuilt layout before you’ll see anything here. 🙂